Medicines Optimisation and Physical Health Safety in Mental Health Services: Monitoring That Actually Works

Medicines can be stabilising and life-changing, but they also introduce predictable physical health risks that services must manage reliably. Within the Physical health, dual diagnosis and parity of esteem resources and the wider Mental health service models and pathways collection, the operational gap is often the same: monitoring schedules exist on paper, but blood tests are missed, side effects go unreported, escalation is inconsistent, and responsibility is unclear. This article sets out a monitoring model that “closes the loop” and produces evidence commissioners and inspectors can trust, without turning support into coercion.

Where medicines-related harm actually comes from

In day-to-day delivery, medicines-related harm is rarely a single error. It more often arises from drift and fragmentation: tests not booked, results not reviewed, symptoms normalised, and no-one owning follow-up. Dual diagnosis and social factors can intensify risk through dehydration, poor nutrition, missed appointments, or unsafe combinations of prescribed and non-prescribed substances.

A practical model focuses on four repeatable tasks:

• Scheduling (what is due, when, and who ensures it is booked).
• Symptom surveillance (how side effects are spotted early in routine contact).
• Escalation (clear thresholds and routes to prescribers/primary care).
• Follow-through (documented outcomes, not just actions attempted).

The operating model: monitoring that is reliable and auditable

1) A medicines monitoring register owned by the service

High-performing services maintain a simple register for people on medicines with defined monitoring requirements. The register records: what monitoring is due, the last completion date, the next due date, and status (booked/attended/results received/actioned). The purpose is not clinical micromanagement; it is preventing “nobody noticed” harm.

2) A consent-led engagement approach that removes barriers

Many missed tests are not refusal; they are barriers: anxiety, trauma, chaotic routines, or distrust. Services should embed reasonable adjustments: supported booking, reminders, accompaniment, quiet waiting options, longer appointments, and practical transport planning. Where a person declines, the service documents informed choice, explains risks in plain language, and revisits at agreed times.

3) Side-effect monitoring built into routine contact

Services should standardise simple side-effect prompts relevant to the medicines used (for example: weight change, sedation, dizziness, constipation, tremor, thirst, urinary symptoms). Staff do not need to diagnose; they need to notice change and trigger escalation when thresholds are met. This is particularly important where people may under-report symptoms due to stigma, poor insight, or fear of medication being changed.

4) Clear escalation thresholds and response times

A defensible model defines what triggers escalation and within what time. Examples include: severe constipation, rapid weight change, fainting episodes, marked sedation affecting safety, persistent vomiting/dehydration, or suspected interaction with substances. Escalation routes should include the prescriber and primary care, and be documented with consent boundaries.

Operational examples (minimum three)

Operational example 1: Preventing serious constipation and dehydration risk

Context: A person on psychotropic medication reports reduced appetite and abdominal discomfort. They are embarrassed and do not volunteer detail. They have a history of A&E attendance for dehydration.

Support approach: The service uses routine side-effect prompts to identify risk early and applies a clear escalation pathway, while providing practical support to reduce harm.

Day-to-day delivery detail: Staff ask a standardised, respectful set of questions during a routine visit and identify constipation risk. They support immediate practical steps (hydration plan, fibre intake, safe activity) and, per escalation threshold, contact the prescriber/GP for same-week review. If the person consents, staff support booking and attending the GP appointment and document the outcome (treatment plan, review date). Staff increase contact for one week to monitor symptoms and ensure the plan is followed, then step down once stable.

How effectiveness is evidenced: Evidence includes documented symptom identification, timely escalation, a recorded treatment plan, and reduced urgent presentations. Case notes demonstrate closed-loop follow-up rather than one-off advice.

Operational example 2: Managing interaction risk in dual diagnosis

Context: A person with serious mental illness uses alcohol and occasionally non-prescribed sedatives. They are stable day-to-day but have episodes of blackout and falls, increasing safeguarding concern.

Support approach: The service uses harm-reduction and safety planning alongside medicines risk management, avoiding punitive approaches that drive non-disclosure.

Day-to-day delivery detail: Staff complete a joint safety plan that includes: identifying high-risk combinations, agreeing “red flag” symptoms requiring urgent help, and ensuring the person has a clear route to disclose use without threat of discharge. With consent, the service communicates key risk information to the prescriber and coordinates with substance misuse support. Staff implement a brief weekly check focusing on sedation, falls risk, hydration, and missed doses. If risks increase (falls, blackouts), escalation is triggered and contact intensity increases until stabilised.

How effectiveness is evidenced: Evidence includes increased disclosure, reduced falls incidents, and documented multi-agency coordination. The service shows risk management that supports honesty and reduces harm rather than driving risk underground.

Operational example 3: Closing the loop on overdue monitoring tests

Context: A person repeatedly misses blood tests due to anxiety and poor sleep. Monitoring is overdue, but records show only repeated “reminders sent”.

Support approach: The service treats overdue monitoring as an operational risk requiring barrier removal, reasonable adjustments, and documented outcome.

Day-to-day delivery detail: Staff book an appointment at a quieter time, arrange accompaniment, and agree a step-by-step plan: prepare the night before, transport route, and a debrief afterwards. If needle anxiety is significant, staff liaise with primary care to explore appropriate options (longer appointment time, supportive positioning, clear explanation). The medicines monitoring register is updated with status changes (booked/attended/results received). When results return, staff ensure the person understands the outcome and that any required medication review or follow-up test is scheduled, not merely suggested.

How effectiveness is evidenced: Evidence includes the completed test, recorded results review, and documented follow-up actions. Audit sampling shows a shift from “contact attempts” to “completed monitoring outcomes”.

Explicit expectations (mandatory)

Commissioner expectation

Commissioners typically expect providers to evidence safe medicines practice through reliable monitoring and follow-up, especially where contracts serve people with serious mental illness and dual diagnosis. They will look for clear process ownership, reasonable adjustments to reduce DNAs, and reporting that demonstrates completed monitoring and actions taken on abnormal results, not just reminders or advice.

Regulator / Inspector expectation (e.g., CQC)

Inspectors typically expect medicines-related risks to be recognised, managed and escalated appropriately. They will look for clear records showing monitoring schedules are followed, side effects are identified early, consent-led information sharing is in place, and safeguarding concerns (falls risk, self-neglect, interaction risk) are addressed. They will also expect learning and improvement when monitoring fails.

Governance and assurance mechanisms

• Monthly medicines safety audit sampling cases for: monitoring due dates, completion, results review, and follow-up actions.
• Exception reporting for overdue monitoring beyond a defined threshold, requiring management oversight and action plans.
• Supervision prompts focusing on one medicines-risk case monthly, including consent, barriers, and escalation decisions.
• Incident review linkage ensuring falls, dehydration episodes, or deterioration reviews consider medicines and monitoring factors.

Monitoring that “actually works” is monitoring that closes loops. It is visible, owned, barrier-aware, and evidenced through completed actions and reviewed outcomes—supporting parity of esteem in real operational terms.

---